INVO Bioscience

IINVO BioScience, Inc. is a fertility company. It focuses on the creation of treatment options for patients diagnosed with infertility. It offers a patented medical device that is used for infertility treatment under the name INVOcell. The company was founded by Kathleen Karloff and Claude Ranoux on January 5, 2007 and is headquartered in Sarasota, FL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NAYA Biosciences, Inc. operates a revenue-generating fertility business. It also focuses on the development of class clinical-stage assets in oncology and autoimmune diseases. The company was founded on October 14, 2024 and is headquartered in Sarasota, FL.

SARASOTA, Fla., July 14, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the appointment of Barbara Levy, M.D.

INVO Bioscience Appoints Barbara Levy as Senior VP, Global Clinical Integration

SARASOTA, Fla. and ATLANTA, June 30, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the signing of a joint venture agreement in partnership with reproductive specialist Dr. Sue Ellen Carpenter, M.D.

INVO Bioscience Signs Joint Venture Agreement with Bloom Fertility to Open an INVOcell Fertility Clinic in Atlanta

SARASOTA, Fla., June 15, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the appointment of Andrea Goren as the Company's chief financial officer.

INVO Bioscience Appoints Andrea Goren as Chief Financial Officer

INVO Bioscience, Inc. (INVO) CEO Steve Shum on Q1 2021 Results - Earnings Call Transcript

SARASOTA, Fla., May 17, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced financial results for the first quarter of 2021 ended March 31, 2021 and provides a business update.

INVO Bioscience Reports First Quarter 2021 Financial and Operating Results and Provides Business Update

SARASOTA, Fla., May 11, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its first quarter 2021, ended March 31, 2021, after the market close on Monday, May 17, 2021.

INVO Bioscience to Report First Quarter 2021 Financial Results on Monday, May 17, 2021

SARASOTA, Fla., May 10, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, is pleased to announce the appointment of tenured women's health & fertility solution marketing professional, Meryle Lynn Chamberlain, as Director of Marketing, a newly created position within the company.

INVO Bioscience Appoints Meryle Lynn Chamberlain to Lead Marketing for Global Brand Expansion

SARASOTA, Fla., April 26, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the appointment of Rebecca Messina to the Company's board of directors, effective immediately.

INVO Bioscience Announces Appointment of Rebecca Messina to the Board of Directors

SARASOTA, Fla., April 22, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced that it has joined in supporting RESOLVE: The National Infertility Association, a non-profit action-based, infertility and family building advocacy organization who strive for increased access to all family building options.

INVO Bioscience Joins in Supporting RESOLVE: The National Infertility Association During its National Infertility Awareness Week (NIAW)

SARASOTA, Fla. and SAN FRANCISCO, April 19, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the execution of a partnership agreement with Lyfe Medical, LLC ("Lyfe Medical") focused on the expansion of the INVOcell solution in Northern California (with an area population of ~8 million people).

INVO Bioscience Signs Partnership Agreement with Lyfe Medical to Establish INVOcell Clinic in Northern California

SARASOTA, Fla., April 12, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, announced today that Steve Shum, CEO of INVO Bioscience, will present at Tribe Public's Webinar Presentation and Q&A Event titled "Democratizing Infertility - A Severely Underserved Global Market.

INVO Bioscience to Present at Tribe Public Event on April 13, 2021

INVO Bioscience's (INVO) CEO Steve Shum on Q4 2020 Results - Earnings Call Transcript

SARASOTA, Fla., March 30, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced financial results for the year ended December 31, 2020.

INVO Bioscience Reports 2020 Financial Results

SARASOTA, Fla., March 29, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, announced today that it will present at the Lytham Partners Spring 2021 Investor Conference on Thursday, April 1, 2021 at 4:15pm ET.

INVO Bioscience to Present at the Lytham Partners Spring 2021 Investor Conference

SARASOTA, Fla., March 26, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its fourth quarter and fiscal year 2020, ended December 31, 2020, after the market close on Tuesday, March 30, 2021.

INVO Bioscience to Report Fourth Quarter and Fiscal Year 2020 Financial Results on Tuesday, March 30, 2021

The stock price of Invo Bioscience Inc (NASDAQ: INVO) has increased by over 20% pre-market. This is why it happened.

INVO Stock Price Increases Over 20% Pre-Market: Why It Happened

INVO Bioscience Achieves Key Milestone - Signs Agreement to Open First Joint Venture INVOcell Clinic in the United States

SARASOTA, Fla., March 11, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced it will participate in the 33rd Annual ROTH Conference, which will be held virtually from March 15-17, 2021.

INVO Bioscience to Participate in the 33rd Annual Roth Conference

The stock price of Invo Bioscience Inc (NASDAQ: INVO) increased by 202.25%. This is why it happened.

INVO Stock Price Increased 202.25%: Why It Happened

Shares of INVO Bioscience, Inc. (NASDAQ: INVO) gained more than 202% in the regular trading session on Tuesday. What Happened: The sharp gains came after the Sarasota, Massachusetts-based medical device company said it has amended its exclusive U.S. commercialization agreement with Ferring Pharmaceuticals.

Why INVO Bioscience Shares Jumped 202% Today

INVO stock is on the move Tuesday after INVO Bioscience announced plans to expand its fertility clinic footprint. The post INVO Stock: Why INVO Bioscience Is Skyrocketing Today appeared first on InvestorPlace.

INVO Stock: Why INVO Bioscience Is Skyrocketing Today

Invo Bioscience Inc (NASDAQ: INVO) shares have gained sharply after an amendment under its exclusive U.S. commercialization agreement with Ferring Pharmaceuticals. The amendment provides an increase in the number of INVO company-owned clinics initially allowable under the agreement and removes certain geographical restrictions.

Invo Bioscience Stock Rallies After Amended Agreement Expands Company-Owned Clinics In US

The stock price of Invo Bioscience Inc (NASDAQ: INVO) is trading at over 100% pre-market as of 4:38 AM ET. This is why it happened.

INVO Stock Price Increased Over 100% Pre-Market: Why It Happened

SARASOTA, Fla., March 8, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility,...

INVO Bioscience Expands Company-Owned Clinic Opportunity Under Amended U.S. Commercialization Agreement

SARASOTA, Fla., March 1, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility,...

News for INVO Bioscience Stock (INVO)